RJA
BTAI icon

Raymond James & Associates’s BioXcel Therapeutics BTAI Stock Holding History

Raymond James & Associates’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,108
Closed -$22.7K – 4005
2024
Q2 		$22.7K Sell
1,108
-50
-4% -$1.67K ﹤0.01% 3876
2024
Q1 		$52.3K Sell
1,158
-26
-2% -$1.24K ﹤0.01% 3798
2023
Q4 		$55.9K Buy
1,184
+135
+13% +$7.5K ﹤0.01% 3696
2023
Q3 		$42.4K Sell
1,049
-117
-10% -$11.8K ﹤0.01% 3686
2023
Q2 		$124K Buy
1,166
+288
+33% +$95.9K ﹤0.01% 3581
2023
Q1 		$262K Sell
878
-118
-12% -$50.4K ﹤0.01% 3326
2022
Q4 		$342K Buy
996
+247
+33% +$59.7K ﹤0.01% 3136
2022
Q3 		$142K Sell
749
-21
-3% -$4.88K ﹤0.01% 3539
2022
Q2 		$163K Buy
770
+86
+13% +$18.1K ﹤0.01% 3572
2022
Q1 		$229K Buy
+684
New +$198K ﹤0.01% 3591
2021
Q4 		– Sell
-508
Closed -$247K – 4148
2021
Q3 		$247K Buy
508
+55
+12% +$24.2K ﹤0.01% 3549
2021
Q2 		$211K Buy
+453
New +$247K ﹤0.01% 3650
2020
Q4 		– Sell
-1,009
Closed -$700K – 3778
2020
Q3 		$700K Buy
+1,009
New +$758K ﹤0.01% 2406

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Raymond James & Associates's BTAI Position: Q3 2024 in Review

Raymond James & Associates sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 1,108 shares — an estimated $22.7K sold.

Raymond James & Associates first reported a position in BTAI in Q3 2020 and held it in 13 quarters. The position peaked at $700K in Q3 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Raymond James & Associates reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 1,108 BioXcel Therapeutics shares in Q3 2024, an estimated $22.7K.
  • Raymond James & Associates first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 13 quarters.
  • Raymond James & Associates's BioXcel Therapeutics position peaked at $700K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.